GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its ...

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration has granted a breakthrough therapy designation to its treatment for a form of bone cancer.

The European stock markets closed mostly higher in Tuesday trading as The Stoxx Europe gained 0.34%, Germany's DAX rose 0.66%, France's CAC increased 0.59%, the Swiss Market Index climbed 1.19%, while ...

London: GSK plc has announced that the US Food and Drug Administration (USFDA) has granted Breakthrough Therapy Designation ...

The coveted designation for GSK5764227 (GSK'227, previously known as HS-20093) is for the use of the ADC to treat relapsed or refractory extensive-stage small-cell lung cancer (SCLC) and comes ...

US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...

The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung cancer (SCLC), with the EMA awarding Priority Medicine (PRIME) status to the ...